Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Go back to Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema| (NASDAQ: PHVS) | Delayed: 32.35 -0.64 (1.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.99 | 52 Week High | $ | |||
| Open | $33.08 | 52 Week Low | $ | |||
| Day High | $33.62 | P/E | N/A | |||
| Day Low | $32.14 | EPS | $ | |||
| Volume | 214,488 | |||||
